DEFA14A: Accuray Appoints New CEO, Board Sponsor Amid Transformation

Accuray Incorporated announced a significant organizational, strategic, and operational transformation, appointing Steve La Neve as CEO and Steven F. Mayer as Transformation Board Sponsor, alongside preliminary Q1 2026 financial results.

Summary

• Accuray is initiating a significant organizational, strategic, and operational transformation to accelerate performance and growth.
• Stephen La Neve has been appointed President and Chief Executive Officer, effective October 20, 2025, and also joined the Board as a Class III director.
• Suzanne Winter resigned as President and CEO and Board member, effective October 19, 2025, and will serve as an advisor through November 30, 2025, for a smooth transition.
• Steven F. Mayer, a current Board member, has been appointed Transformation Board Sponsor through a consulting agreement with his affiliate, Dedication Capital, LLC, effective October 20, 2025.
• Dedication Capital and Mr. Mayer will receive a base consulting fee of $600,000 per year, a target cash incentive of $531,250 for fiscal year 2026 (minimum $265,625), and equity awards totaling 2,500,000 shares (1,250,000 restricted stock awards (RSAs) and 1,250,000 performance-based restricted stock awards (PRSAs)).
• Mr. La Neve's compensation package includes an annual base salary of $750,000, a target annual bonus of 100% of his base salary (guaranteed minimum 50% for fiscal year 2026), and initial equity awards of 1,250,000 restricted stock units (RSUs) and 1,250,000 performance-based RSUs (PSUs).
• Mr. La Neve is also expected to receive a refresh equity award in November 2025 with a grant date fair value of $2,300,000, comprised of 50% RSUs and 50% PSUs.
• Suzanne Winter's separation agreement includes continued base salary through November 30, 2025, cash severance of $750,000, a $50,000 payment in lieu of target bonus, reimbursement of COBRA premiums for 14 months, and continued vesting of outstanding equity awards through November 30, 2025, contingent on advisory services.
• Preliminary financial results for the first quarter ended September 30, 2025, indicate total revenues of $92.5 million to $94 million and an adjusted EBITDA of approximately ($4) million.
• Product revenues were below expectations in EIMEA and China, while service revenues were ahead of plan, with geographic sales mix and joint venture accounting negatively impacting product gross margins.
• Chan W. Galbato has been nominated to the Board of Directors to further support the transformation and growth strategy.

Sentiment

Score: 5

Explanation: The filing presents a mixed outlook. The appointment of experienced leadership and the initiation of a strategic transformation plan are positive steps aimed at improving future performance and profitability. However, the preliminary Q1 2026 financial results, showing negative adjusted EBITDA and underperforming product revenues, are a significant concern. The success of the transformation is not guaranteed, and the substantial equity compensation for new leadership could lead to dilution.

Positives

• Appointment of highly experienced industry leaders, Stephen La Neve as CEO and Steven F. Mayer as Transformation Board Sponsor, to drive strategic and operational improvements.
• The transformation plan aims to increase operating margins, enhance organizational responsiveness and agility, and position the company for sustainable, profitable growth.
• Management expects to achieve a high single-digit adjusted EBITDA margin run-rate within twelve months, with a goal to expand to double digits over the medium to long term.
• The company reports a robust installed base and rapidly increasing presence in several fast-growing global markets.
• Service revenues for Q1 2026 were ahead of plan, indicating strength in recurring revenue streams.
• TCW, the company's strategic lending partner, has expressed strong support for the transformation plan and leadership changes, suggesting confidence from a key financial stakeholder.

Negatives

• Preliminary adjusted EBITDA for Q1 2026 is approximately ($4) million, indicating a loss for the quarter.
• Product revenues for Q1 2026 were below expectations in the EIMEA (Europe, India, Middle East, and Africa) region and China.
• Geographic sales mix and joint venture accounting adversely impacted product gross margins in Q1 2026.
• The significant compensation packages for new executives and consultants, including substantial equity awards, could lead to future shareholder dilution.

Risks

• The ability to successfully execute the announced transformation plan and realize its intended benefits.
• The impact of the global macroeconomic environment on the company's operations, customers, and suppliers.
• Disruptions to the company's supply chain, including potential increases in logistics costs.
• Challenges in achieving widespread market acceptance for the company's products.
• The company's substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt.
• The potential effect of enhanced international tariffs on the company's business.
• The ability to realize the expected benefits from the China joint venture and other strategic partnerships.
• Risks inherent in international operations, including currency fluctuations and geopolitical factors.
• The ability to maintain or increase gross margins on product sales and services.
• Potential delays in regulatory approvals or the development and release of new product offerings.
• The ability to convert existing order backlog into recognized revenue in a timely manner.

Future Outlook

The company is undertaking a significant organizational, strategic, and operational transformation to increase operating margins, enhance organizational responsiveness and agility, and position for sustainable, profitable growth. Management expects to achieve a high single-digit adjusted EBITDA margin run-rate within twelve months and aims to expand that margin to double digits over the medium to long term.

Management Comments

• "With Accuray's transformation plan well underway, these leadership appointments are proactive steps to add momentum and position the company for long-term success." Joe Whitters, Chairman of the Board.
• "Steve's proven record of operational excellence and value creation at leading med-tech companies makes him exceptionally well suited to guide Accuray through its next phase of growth." Joe Whitters, Chairman of the Board.
• "Accuray's mission to deliver the curative power of radiation therapy to patients around the world is both inspiring and urgent." Stephen La Neve, CEO.
• "We will execute our transformation plan with clarity, confidence, and purpose to enhance our competitiveness and create long-term value for the patients, providers, and shareholders we serve." Stephen La Neve, CEO.
• "I'm excited to partner with Steve La Neve and the Board to accelerate Accuray's transformation." Steven F. Mayer, Transformation Board Sponsor.
• "We expect to reach a high single-digit adjusted EBITDA margin run-rate within twelve months and to expand that margin to double digits over the medium to long term." Steven F. Mayer, Transformation Board Sponsor.

Industry Context

Accuray operates in the highly specialized and impactful medical technology sector, specifically radiation oncology. The company's strategic and operational transformation, coupled with new leadership, reflects a common industry trend where companies seek to optimize efficiency, enhance competitiveness, and drive profitable growth amidst evolving market dynamics and technological advancements. The focus on expanding margins and improving customer focus aligns with broader industry pressures for innovation and value delivery in healthcare.

Comparison to Industry Standards

• Stephen La Neve brings over 40 years of international medical-technology experience, including leadership roles at Globus Medical Inc. (NYSE: GMED), Bone Biologics Corporation (NASDAQ: BBLG), Becton Dickinson Preanalytical Systems (NYSE: BDX), and Medtronic's Spine and Biologics Division (NYSE: MDT), indicating a background with established industry players.
• Steven F. Mayer's experience includes nearly two decades at Cerberus Capital Management and serving as Executive Chairman of global healthcare company Grifols, S.A., where he designed and led a company-wide transformation that delivered over €400 million in annual cost savings, demonstrating a track record in large-scale corporate restructuring.
• Chan W. Galbato, nominated to the Board, has over 30 years of operational and strategic leadership experience across global enterprises, including senior executive roles at Albertsons Companies, Cerberus Operations and Advisory Company, Invensys, The Home Depot, and GE, providing a broad perspective on operational excellence and strategic growth.

Management Changes

Corporate Governance

Related Party Transactions

• Accuray Incorporated entered into a consulting agreement with Dedication Capital, LLC, an affiliate of Steven F. Mayer, who is a member of the company's Board of Directors.
• Under the agreement, Mr. Mayer, as CEO of Dedication Capital, will serve as the company's Transformation Board Sponsor.
• Dedication Capital and Mr. Mayer will receive a base consulting fee of $600,000 per year, cash incentive awards (target $531,250 for FY2026 and $218,750 for Q1 FY2027), and equity awards totaling 2,500,000 shares (1,250,000 RSAs and 1,250,000 PRSAs).
• The independent members of the Board approved this consulting agreement, acknowledging it as a related party transaction under Item 404 of Regulation S-K.

Stakeholder Impact

• Shareholders: Potential for significant share price volatility due to major leadership changes and a strategic transformation. The preliminary negative Q1 EBITDA is a concern, but the long-term goals of margin expansion could be beneficial. New equity awards for leadership may lead to dilution.
• Employees: The organizational, cultural, and operational initiatives led by the new CEO and Transformation Board Sponsor will likely impact employee roles, structures, and potentially morale.
• Customers: The transformation aims to enhance competitiveness and customer focus, which could lead to improved products, services, and overall customer experience.
• Management: A complete overhaul of top leadership, with a new CEO and a dedicated Transformation Board Sponsor, signals a new strategic direction and operational approach.
• Creditors/Lenders: The company's strategic lending partner, TCW, has expressed strong support for the transformation plan, which is positive for creditor confidence, especially given the company's substantial outstanding indebtedness.

Next Steps

• Steven F. Mayer will lead the company's planning and execution of strategic, organizational, cultural, and operational initiatives and transformation.
• Steven F. Mayer will establish the composition and duties of a Transformation Office.
• The company will seek stockholder approval for the 2026 Equity Incentive Plan at its 2025 Annual Meeting of Stockholders.
• Stephen La Neve is required to relocate to the Madison, Wisconsin greater metropolitan area by January 1, 2026.
• The company expects to release summary financial information for its fiscal 2026 first quarter on November 5, 2025.
• The Board will determine performance metrics for Steven F. Mayer's and Stephen La Neve's incentive awards.
• Stephen La Neve is expected to receive a refresh equity award in November 2025, subject to Board approval.

Key Dates

Recommendation

The company is embarking on a significant transformation with new, experienced leadership and ambitious goals to improve operating margins and profitability. This strategic shift could be a long-term positive, but its success is not guaranteed. The immediate financial results for Q1 2026 are weak, showing negative adjusted EBITDA and underperforming product revenues, which creates near-term uncertainty. The substantial equity compensation for new leadership could also lead to dilution. Investors should hold to observe the execution of the transformation plan and await more concrete evidence of improved financial performance before considering further investment.

Keywords

Accuray, ARAY, CEO change, executive appointment, board sponsor, corporate transformation, financial results, Q1 2026, adjusted EBITDA, revenue, medical technology, radiation oncology, corporate governance, equity awards, related party transaction, strategic initiatives